Clinical Trials Logo

Clinical Trial Summary

DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05050006
Study type Interventional
Source Instil Bio
Contact
Status Terminated
Phase Phase 2
Start date October 7, 2021
Completion date February 27, 2023

See also
  Status Clinical Trial Phase
Completed NCT01511913 - A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma